JWH-133

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
JWH-133
JWH-133.png
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
ChEMBL
Chemical and physical data
Formula C22H32O
Molar mass 312.489 g/mol
3D model (JSmol)
 NoYesY (what is this?)  (verify)

JWH-133 is a potent selective CB2 receptor agonist with a Ki of 3.4nM and selectivity of around 200x for CB2 over CB1 receptors. It was discovered by and named after, John W. Huffman.

JWH-133, alongside WIN 55,212-2 and HU-210, is responsible for preventing the inflammation caused by Amyloid beta proteins involved in Alzheimer's Disease, in addition to preventing cognitive impairment and loss of neuronal markers[citation needed]. This anti-inflammatory action is induced through agonist action at cannabinoid receptors, which prevents microglial activation that elicits the inflammation. Additionally, cannabinoids completely abolish neurotoxicity related to microglia activation in rat models.[citation needed]

It may be linked with anti-cancer properties, according to pre-trial data from a 2010 study in Madrid.[1]

Legal Status[edit]

The substance commonly referred to as "JWH-133" is not a scheduled substance in the U.S, except in Alabama.[2] Low abuse potential makes it less likely for regulation relative to its sister drugs such as JWH-018, as JWH-133 is selective for the non-psychoactive CB2 receptor and thus lacks significant psychoactive effects.[3]

References[edit]

External links[edit]

  • JNeurosci.org Prevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation Also has been shown to block grown of tumors. More clinical studies and trials are needed.